Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.

Abstract

PURPOSE:

This post-hoc analysis of 2 studies investigated the safety and efficacy of weekly and every-3-week (q3w) nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in older patients with metastatic breast cancer (MBC) compared with q3w solvent-based paclitaxel and docetaxel.

RESULTS:

Patients≥65 years (median: 69) were analyzed. In phase 2 (n=52), overall response rates (ORR) for weekly nab-paclitaxel were 60-64% vs 22% for q3w nab-paclitaxel and 32% for docetaxel. In phase 3 (n=62), ORRs were 27% for q3w nab-paclitaxel and 19% for solvent-based paclitaxel. In phase 2, median progression-free survival (PFS) was 18.9 months for 150 mg/m2 weekly nab-paclitaxel vs 8.5-13.8 months for all other regimens. In phase 3, median PFS for q3w nab-paclitaxel and solvent-based paclitaxel were 5.6 months and 3.5 months, respectively. Weekly nab-paclitaxel resulted in less serious adverse events compared with all other regimens.

CONCLUSIONS:

Weekly nab-paclitaxel was safe and more efficacious compared with the q3w schedule and with solvent-based taxanes in older patients with MBC.

• Authors: Matti Aapro, Sergei Tjulandin, Paul Bhar, William Gradishar
• Journal: Breast (Edinburgh, Scotland) (Breast) Vol. 20 Issue 5 Pg. 468-74 (Oct 2011) ISSN: 1532-3080 [Electronic] Netherlands
• PMID: 21843943 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• 130-nm albumin-bound paclitaxel
• Albumins
• Antineoplastic Agents
• Taxoids
• Docetaxel
• Paclitaxel

Topics

• Aged
• Aged, 80 and over
• Albumins (administration & dosage)
• Antineoplastic Agents (administration & dosage)
• Brain Neoplasms (drug therapy, mortality, secondary)
• Breast Neoplasms (drug therapy, mortality, pathology)
• Disease-Free Survival
• Docetaxel
• Drug Administration Schedule
• Female
• Humans
• Liver Neoplasms (drug therapy, mortality, secondary)
• Lung Neoplasms (drug therapy, mortality, secondary)
• Neoplasm Metastasis
• Paclitaxel (administration & dosage)
• Pelvic Neoplasms (drug therapy, mortality, secondary)
• Taxoids (administration & dosage)
• Treatment Outcome